Skip to navigationSkip to contentSkip to footerHelp using this website - Accessibility statement

Sigma Healthcare Limited

The traditional full line pharmacy wholesale distribution business, retail and private label products. Also has national Presence in the hospital pharmacy distribution market, and through its network infrastructure, provides third party and fourth party logistics services. The Group also operates one of Australia's pharmacy networks, across the brands Amcal, Guardian, Chemist King, Discount Drug Stores, WholeLife, and PharmaSave.

SIG$0.970
 -0.020 -2.02%

Data last updated:Dec 21, 2023 – 12.18pm. Data is 20 mins delayed.

Previous Close

0.990

Open

0.975

Day Range

0.970 - 0.990

52 Week Range

0.572 - 1.350

Volume

18,232,804

Value

3,167,656

Bid

0.970

Ask

0.975

Dividend Yield

0.99%

P/E Ratio

70.42

Market Cap

994.330M

Total Issue

1,313,332,906

ASX Announcements

Change in substantial holding

Change in substantial holding

  • Dec 20, 2023
  • 3 pages

Change of Director's Interest Notice

Change of Director’s Interest Notice

  • Dec 20, 2023
  • 3 pages

Application for quotation of securities - SIG

Appendix 2A (Application for Quotation of Securities)

  • Dec 19, 2023
  • 5 pages

Market Sensitive

Retail Offer Booklet and Letters to Retail Shareholders

Company Presentation, Non-Renounceable Issue, Letter to Shareholders

  • Dec 18, 2023
  • 284 pages

Change in substantial holding

Change in substantial holding

  • Dec 15, 2023
  • 4 pages

View all SIG announcements

This Month

EY has outed itself.

EY cuts poor performing, misbehaving partners

More than 40 partners have left big four consulting firm EY in the second half of 2023, more than half because of poor performance, or behaviour issues.

  • Edmund Tadros
The Chanticleer podcast features James Thomson and Anthony Macdonald.

AFR Business People of the Year | What CEOs want | Inside Chemist Warehouse

In this week’s episode, James and Anthony take a deep dive into what CEOs want to see from Anthony Albanese in 2024 and discuss the astounding Chemist Warehouse deal.

Mark Finocchiaro, managing partner Chemist Warehouse, owns eight pharmacies in the group.

Inside the Chemist Warehouse franchisee world

There are over 200 managing partners who are shareholders in the discount chain. They are all ambitious pharmacy owners, many with multiple sites.

  • Carrie LaFrenz
HMC Capital’s David Di Pilla has pulled off another big win.

Chemist Warehouse deal just part of David Di Pilla’s big plan

In helping to bring the retail giant and Sigma together, he is playing the long game and hopes to create a “mini Blackstone” in Australia.  

  • James Thomson
Sigma’s deal suggests bulls are running and will have bankers ready to start the new year with a bang.

Sigma’s 40pc pop: a FOMO story on a Chemist Warehouse scale

Too bad Chemist Warehouse came just as investors are winding down for Christmas. Can the FOMO survive the break?

  • Anthony Macdonald
Advertisement
Chemist Warehouse has grown into one of the largest retailers in the country and will list on the ASX through Sigma Healthcare.

HMC Capital opens back door to Sigma-Chemist Warehouse deal

Street Talk understands about 80 brokers tuned in for a lunchtime briefing from the asset manager on Wednesday.

  • Sarah Thompson, Kanika Sood and Emma Rapaport
An “extraordinary” $2 billion raised this year: David Di Pilla

David Di Pilla’s lucky streak at Sigma

Di Pilla’s HMC will emerge with a board seat and around 3 per cent of the new company, should the deal go through

  • Sarah Thompson, Kanika Sood and Emma Rapaport
Sigma Healthcare CEO Vikesh Ramsunder, and Chemist Warehouse co-founder, Mario Verrocchi (R) both will remain in the combined business valued at $8.8 billion.

Sigma could shed customers after Chemist Warehouse merger

The deal, creating an $8.8 billion retail and wholesaling giant, could even be blocked by competition regulators, according to analysts at Morningstar.

  • Carrie LaFrenz and Tom Richardson
Josh and Amie Frydenberg with Laura and Mark Davis at the Australian Open men’s final.

Sigma’s advisers kept Chemist Warehouse close

Sigma’s board no doubt pushed for as good a deal as they could get. The motivations of their advisers, though, are complex.

  • Updated
  • Myriam Robin
Chemist Warehouse

‘Like Bunnings’: Fund managers bullish on Chemist Warehouse

Investors are optimistic that the pharmacy chain is among the best retailers in the country, and has enough room to grow at home to justify its valuation.

  • Tom Richardson
Jack Gance and Mario Verrocchi are set to storm onto the ASX boards.

Why Chemist Warehouse creates a quandary for fund managers

The structure of Chemist Warehouse’s deal with Sigma means fund managers who like the growth story face tough decisions on when and how to get a slice of the action.

  • Updated
  • James Thomson
HMC Capital’s David Di Pilla and Victoria Hardie lobbed the idea for Chemist Warehouse over a sushi dinner at Nobu in Melbourne.

How David Di Pilla dreamt up the Chemist Warehouse deal over sushi

Five months ago, over a sushi dinner at Melbourne’s Nobu, Sigma boss Vikesh Ramsunder and his major shareholder David Di Pilla were toasting a win. Then the lightbulb moment hit.

  • Aaron Weinman
Jack Gance and Mario Verrocchi have climbed the Financial Review Rich List after sticking a deal to list their company on the ASX.

Chemist Warehouse duo to climb Rich List after Sigma deal

Documents associated with the merger, which will create a retail giant, show for the first time the precise shareholdings of Jack Gance and Mario Verrocchi.

  • Michael Bailey
Vikesh Ramsunder will remain the chief executive of Sigma Healthcare, while Mario Verrocchi will run the Chemist Warehouse business.

Chemist Warehouse’s 100-year plan to be the next Walgreens

Chemist Warehouse CEO Mario Verrocchi says the retailer could become the next Walgreens or Boots and expand rapidly overseas after becoming an $8.8 billion ASX-listed pharmacy giant.

  • Updated
  • Carrie LaFrenz
Jack Gance and Mario Verrocchi are set to storm onto the ASX boards.

The 100-year dream that powers Chemist Warehouse

The company is on the verge of achieving a 50-year dream with the $8.8 billion Sigma merger. It insists there’s plenty of growth to come.

  • Updated
  • James Thomson
Advertisement
Chemist Warehouse CEO Mario Verrocchi is bullish about the company’s international growth prospects.

Chemist Warehouse boss targets growth of ‘infinity and beyond’

Mario Verrocchi, one of the billionaire founders of the pharmacy chain, says international expansion will be a key focus for the company as it joins the ASX.

  • Simon Evans
Sigma Healthcare deal could be the M&A transaction of the year.

Chemist Warehouse deal will make Sigma stock a global attraction

The deal name, Project Orbit, says it all. Hats off to this sleepy wholesaler for rocketing into the large-cap universe and catching the eye of US giants.

  • Anthony Macdonald
Sigma chief executive Vikesh Ramsunder will remain at Sigma following merger with Chemist Warehouse.

Chemist Warehouse top brass to remain in Sigma merger

The drug wholesaler and distributor took the weekend to hammer out the last details of the reverse takeover by the pharmacy giant.

  • Carrie LaFrenz
Chemist Warehouse plans to merge with Sigma but The Pharmacy Guild has warned against the deal.

Influential pharmacy lobby comes out against Chemist Warehouse deal

The Pharmacy Guild says the proposed reverse listing of the company into Sigma, creating an $8 billion giant, posed “significant questions and risks”.

  • Carrie LaFrenz
Chemist Warehouse’s deal to list via Sigma Healthcare is due to be signed in coming days.

Eight-year quest to float Chemist Warehouse ends abruptly

Missing Chemist Warehouse’s IPO would be a career limiting move. But when the whole street misses it, play on.

  • Anthony Macdonald

Copyright © 2023. Company information displayed on The Australian Financial Review is sourced from Morningstar and ASX and is subject to their terms and conditions as set out in our Terms of Use. The Australian Financial Review does not accept any responsibility for the accuracy and/or completeness of such data or information.